Who We Are

We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future.

Our unique expertise is in the design and engineering of astonishing living systems, from T-cells that battle cancer to non-browning apples. Across our diverse portfolio of projects we apply a common philosophy: bring together the greatest minds in synthetic biology and empower them to solve big problems.

Our Technologies

intrexon is addressing global challenges with precise control of biological systems across four major biology classes – Microbes, Plants, Animals, Human Cells – to protect our environment, promote health and feed the growing populations of humans and animals. We are driving innovation in new product development through the integration of our technologies and invite you to discover more in our most recent corporate presentation.

Precise Control of Gene Expression. At its core, intrexon is a gene expression and regulation company focused on precise control of a wide collection of cells and organisms. To date, we’ve worked in more than 50 different expression host species. We program cells’ genetic code to drive specific biofunction. We utilize the UltraVector® DNA construction architecture to design and assemble genetic components into complex gene expression programs. Our RheoSwitch® technology for therapeutic applications, as well as, the Florian™ switch for use in plants are first-in-class proprietary molecular switches being used for regulation of gene expression and switching on and off traits (e.g. flowering control).

Design and Engineering of Biosystems. intrexon’s comprehensive knowledge of a broad range of biology classes combined with our bioinformatics and computational biology tools and expertise enables the discovery, generation, and validation of multiple routes for innovative product development. The application of these tools is exemplified in the development of high value production cell lines and microbial strains, including our methane bioconversion platform that has enabled upgrading natural gas to a variety of petrochemical fuel replacements, lubricants, and specialty chemicals via fermentation. This program required elucidation of the complete metabolic networks of the methanotroph, a previously unmapped bacterium that naturally consumes methane, to construct bioinformatic models allowing us to convert natural gas feedstock to valuable products at very high efficiencies.

Engineered Gene Function and Delivery. intrexon’s precision engineering capabilities are differentiated with respect to the controllable, multi-genic payload capacity of our gene programs. Our ability to control gene expression at specific cellular and subcellular locations can be modulated by both viral and non-viral methods depending on the requirements of the specific product. Our AdenoVerse™ platform includes a broad array of proprietary, adenovirus-based vectors for efficient gene delivery of therapeutics and molecular vaccines for human and animal health applications. We also employ non-viral gene delivery approaches in therapeutic programs like our chimeric antigen receptor (CAR) T cell immunotherapy for cancer treatment, which enables engineering of patient cells in the clinical point-of-care setting for a more rapid administration of therapy. For larger payloads, we leverage the AttSite™ recombinase platform that allows us to establish a landing pad in transcriptionally active genomic locations and integrate a gene program with high fidelity at that specified location, ensuring stability and functionality of engineered cells.

better DNA

The random mutation of DNA has produced the amazing diversity of life on our planet. Through a variety of means, humanity has been influencing the biosphere for the last ten millennia in order to favor some outcomes over others – but we did this without an understanding of life’s underlying code. Today, we are able directly to apply human creativity to this code, endowing organisms with capabilities uniquely suited to global needs. Click below for more information on the four classes of organisms in which we are exploring the frontiers of better DNA.

Our Pipeline

Non-browning produce to benefit the food supply chain, from growers to consumers

Product
Description
Proof-of-Concept
In Development
Pilot
In Market
Arctic® Golden Apple
Currently, about 40% of apples grown are wasted each year. The Arctic Advantage™ nonbrowning technology applied to Arctic® Golden apples reduces the amount of polyphenol oxidase (PPO), the enzyme that causes browning, resulting in apples that don’t brown when bitten, sliced, or bruised. Discover More
Arctic® Granny Apple
With the Arctic Advantage™ nonbrowning trait, Arctic® Granny apples can deliver a consistently higher-quality eating experience to consumers, revitalizing the positioning of Granny Smith as one of the healthiest varieties due to high antioxidant and phenolic levels. Discover More
Arctic® Fuji Apple
With the Arctic Advantage™ nonbrowning trait, Arctic® Fuji apples can deliver a consistently higher-quality eating experience to consumers, revitalizing the positioning of Fuji Apples as one of the most widely produced apple varieties in the world. Discover More
Non-browning Avocados
Browning of avocado flesh after exposure to oxygen is a significant problem for producers and consumers. In the period of time from the harvest of an avocado to its final destination, quality and quantity losses of 5-25% can take place due to friction damage. In collaboration with Persea Bio, intrexon is developing improved cultivation techniques and traits for avocados. Discover More
Non-browning Pears
The Arctic Advantage™ nonbrowning technology can be applied to pears by reducing the amount of polyphenol oxidase (PPO), the enzyme that causes browning, resulting in pears that don’t brown when bitten, sliced, or bruised. Discover More
Non-browning Cherries
Currently, about 45% of fruits and vegetables produced are wasted. Nonbrowning cherries can deliver a consistently higher-quality eating experience to consumers, while making the rest of the supply-chain’s job easier. Discover More
Non-browning Lettuce
Browning of lettuce is a problem for consumers. intrexon is developing nonbrowning lettuce that doesn’t brown when sliced or torn. We expect this nonbrowning technology to create significant value for consumers. Discover More

*Our nonbrowning Arctic® apples are developed and marketed under our wholly owned subsidiary Okanagan Specialty Fruits, Inc.

Product
Description
Initial Screening
Proof-of-Concept
Early Development
Advanced Development
Self-Limiting Fall Armyworm
Fall armyworm is a pest of more than 80 kinds of plants and is one of the most difficult pests to control, causing significant production losses. We are working together with a leading agricultural company to develop a self-limiting fall armyworm. These insects contain a ‘self-limiting’ gene, and when male insects are released to mate with wild females, their offspring inherit a copy of this gene. Discover More
Self-Limiting Diamondback Moth
The diamondback moth is one of the most destructive crop pests in the world. This pest is found around the globe and now shows resistance to almost every insecticide. We are engineering a diamondback moth to contain a ‘self-limiting’ gene. Discover More
Self-Limiting Spotted-Wing Drosophila
The spotted-wing Drosophila damages crops of soft and stone fruits like strawberries, blackberries, plums, peaches, and cherries. We are engineering spotted-wing Drosophila to contain a ‘self-limiting’ gene. When male insects are released to mate with wild females, and they do not produce viable offspring, resulting in a reduction of the wild pest population. Discover More
Self-Limiting Medfly
Mediterranean fruit fly (Medfly) is a hugely destructive agricultural pest, attacking more than 250 kinds of fruits, nuts and vegetables. The self-limiting technology can help suppress Medfly as it offers an environmentally responsible solution that overcomes many of the limitations of existing methods. Discover More

*Our self-limiting insects for crop protection are developed under our wholly owned subsidiary intrexon Crop Protection utilizing self-limiting insect technology pioneered by our wholly owned subsidiary Oxitec, Ltd.

Product
Description
Proof-of-Concept
In Development
Pilot
In Market
Enviro™ Bug
EnviroFlight produces dried black soldier fly larvae (BSFL) products including Enviro™ Bug whole BSFL. BSFL are highly efficient in converting nutrients, producing 1-2 million pounds of useable protein per acre annually due to multiple larvae cycles each year, a growth cycle of a few weeks, and the ability to farm vertically. Discover More
Enviro™ Meal
FAO estimates that commercial feed production will need to increase by 70% by 2050 to meet the growing global demand for protein, EnviroFlight technology recovers nutrients from waste food streams to provide a high-protein, sustainable, cost-effective nutrient source to help meet this demand. Discover More
Enviro™ Oil
Enviro™ Oil derived from BSFL. EnviroFlight is the first U.S. company to attain commercial scale BSFL production due to its modular, scalable approach that enables significant protein production capacity within a small footprint. Discover More
Enviro™ Frass
Enviro™ Frass is BSFL frass used for fertilizer. All larvae are grown and dried in the United States in an environmentally responsible manner. Discover More
Enviro™ Feed
Enviro™ Feed is BSFL frass used for feed. EnviroFlight® larvae are grown on pre-consumer byproduct approved by Association of American Feed Control Officials (AAFCO). The larvae vary in protein and fat content based on the diet fed and can be customized to meet customers’ needs. Discover More
BugButter™ Oil
EnviroFlight produces dried black soldier fly larvae (BSFL) products including BugButter™ oil, which is BSFL oil used for cosmetics. Discover More

*Our black soldier fly platform is being developed and marketed through EnviroFlight, our joint venture with Darling Ingredients, Inc.

Product
Description
Gene Targeting
Founders
Characterization
Commercial Research Stage
ExeGen® LDLR+/-
The ExeGen® LDLR MiniSwine has received approval from the U.S. Food and Drug Administration for commercial research use in cardiovascular disease research. This model features targeted disruption of the endogenous LDLR (low-density lipoprotein receptor) gene. Discover More
ExeGen® LDLR-/-
MiniSwine research models are more anatomically, physiologically, and genetically similar to humans than are mice and other small-animal disease models and are designed to provide improved predictive power to the preclinical stages of therapeutic development. Discover More
ExeGen® CFTR-/-
With the ExeGen® CFTR Swine, researchers are able to utilize swine to model cystic fibrosis, a condition that causes severe damage to the lungs and other digestive organs due to abnormal mucus production. Discover More
ExeGen® CFTRF508del/F508del
The ExeGen® CFTR model has a point mutation of the CFTR gene, which is important for normal production of mucus in the body, and offers a platform with greater anatomical, physiological, and genetic similarity to humans, mitigating the lack of translation with murine systems due to differences in size and metabolism. Discover More
ExeGen® SCN5A+/E558X
The ExeGen® SCN5A+/E558X MiniSwine was developed to model Brugada syndrome, a type of cardiac arrhythmia. Brugada syndrome is the most common cause of sudden death in young men without known underlying cardiac disease (implicated in 20% of cases) and thought to be responsible for up to 10% of deaths from sudden infant death syndrome. Discover More
ExeGen® TP53R167H/R167H
With the ExeGen® TP53R167H/R167H MiniSwine, researchers are able to utilize miniature swine to model cancer. The ExeGen® TP53 model expresses mutations in the gene that encodes p53 (TP53), which is orthologous to one commonly found in humans. Discover More
ExeGen® TP53+/R167H & KRAS+/G12D
The ExeGen® TP53 model expresses mutations in the gene that encodes p53 (TP53), which is orthologous to one commonly found in humans and a conditional KRAS mutation. This should allow for the inducement of human-like tumors in a tissue specific manner. Discover More
ExeGen® DMD+/ex52del
With the ExeGen® DMD+/ex52del MiniSwine, researchers are able to utilize miniature swine to model Duchenne muscular dystrophy (DMD), a neuromuscular disorder. With the ExeGen® DMD+/ex52del MiniSwine research model, which has a deletion of a portion of the DMD gene important for the function of muscle, researchers are able to use it to help define and develop effective therapies for DMD. Discover More
ExeGen® ATM-/-
The ExeGen® ATM MiniSwine has received clearance from the U.S. Food and Drug Administration for commercial use as a research model. This model features targeted disruption of the endogenous ATM gene in Yucatan MiniSwine genetics to generate a model that recapitulates ataxia telangiectasia (AT), a rare inherited, predominantly neurological human disease. Discover More
ExeGen® CLN3ex7&8del/ex7&8del
With the ExeGen® CLN3ex7&8del/ex7&8del MiniSwine model, researchers are able to utilize miniature swine to model CLN3 disease or Batten disease, a group of neurodegenerative disorders. With the ExeGen® CLN3ex7&8del/ex7&8del MiniSwine research model, which has deletions in portions of CLN3 gene, researchers are able to use it to help define and develop effective therapies for CLN3 disease. Discover More
ExeGen® HTT+/Ex1+(CAG)n
With the ExeGen® HTT+/Ex1+(CAG)n research models, researchers are now able to utilize miniature swine to model Huntington disease, a fatal neurodegenerative disorder. With the ExeGen® HTT+/Ex1+(CAG)n model, researchers are able to use it to help define and develop effective therapies for Huntington disease. Discover More
ExeGen® MYH7+/R403Q
The ExeGen® MYH7+/R403Q model, has mutations in the MYH7 gene important for heart muscle function, and offers a platform for researchers to use to help define and develop effective therapies for cardiomyopathy. Discover More
ExeGen® NF-1+/-
With the ExeGen® NF-1+/- MiniSwine, researchers are able to utilize miniature swine to model neurofibromatosis type I, a nervous system disorder. The ExeGen® NF 1 model has a deletion of one copy of the NF1 gene important for preventing abnormal cell division in nerve cells. Discover More
ExeGen® PKD+/-
The ExeGen® PKD+/-MiniSwine model has a deletion of one copy of the PKD1 gene important normal development and function of the kidneys. It offers a platform with greater anatomical, physiological, and genetic similarity to humans, mitigating the lack of translation with murine systems due to differences in size and metabolism, and can be used by researchers to help define and develop effective therapies for polycystic kidney disease. Discover More
ExeGen® SCDhHBA/hHBA/hHBG-hHBBS/ hHBG-hHBBS
With the ExeGen® SCDhHBA/hHBA/hHBG-hHBBS/ hHBG-hHBBS MiniSwine, researchers are now able to utilize miniature swine to model the blood disorder sickle cell disease. The development of models of sickle cell disease is part of a subcontract with Leidos Biomedical Research, Inc., prime contractor for the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, part of the National Institutes of Health (NIH). Discover More

*Our miniswine research models are developed and marketed under our wholly owned subsidiary Exemplar Genetics.

Product
Description
Proof-of-Concept
In Development
Pilot
In Market
In Vitro Fertilization
In Vitro Fertilization (IVF) is the process of creating embryos from oocytes (unfertilized egg cells) by fertilizing them with semen in a Petri dish. Oocytes are first collected from the ovaries of donors by ultrasound-guided follicular aspiration. Discover More
Embryo Transfer
Embryo Transfer (ET) is an advanced reproductive technology and a progressive tool that can help produce more offspring from an elite cow and thereby extend the impact of outstanding cattle genetics. Discover More
Fresh Ship Program
Oocytes and embryos can be shipped by Fed Ex or UPS directly to farms and ranches. Embryos can be implanted immediately and provide excellent pregnancy rates. Trans Ova Genetics, offers the option of performing services in-center or on-farm. Discover More
Elite Calf Program
In addition to producing embryos for its clients, Trans Ova can implant bovine embryos, gestate, calve and raise the resulting calves on site. These calves may then be shipped to client farms, or entered into Trans Ova In Vitro Fertilization programs to further increase genetic gain. Discover More
Recipient Options
Embryos can be implanted into recipients owned by Trans Ova Genetics. After pregnancy is confirmed, these recipients can be delivered to the client’s farm, or gestated and calved by Trans Ova Elite Calf program. Discover More
Laparoscopic Artificial Insemination (LAI)
Laparoscopic AI (LAI) is used to properly place the semen in to the uterine horns of small ruminants during a minimally invasive surgery. We recommend the utilization of this procedure as it consistently increases the fertilization rate realized via a flush. Discover More
Embryo Transfer in Small Ruminants
Embryo Transfer (ET) is an advanced reproductive technology and a progressive tool that can help sheep and goat breeders produce more offspring from elite females and can extend the impact of outstanding sheep and goat genetics. Discover More
In Vitro Fertilization in Small Ruminants
In Vitro Fertilization (IVF) is the process of creating embryos from oocytes (unfertilized egg cells) by fertilizing them with semen in a Petri dish. Oocytes are first collected from the ovaries of donors by ultrasound-guided follicular aspiration. Discover More

*Our bovine reproductive technologies are developed and marketed under our wholly owned subsidiary, Trans Ova Genetics.

Media

Press

Intrexon Announces Transfer of Stock Listing to Nasdaq

September 12, 2018

Ticker symbol to remain "XON" Read More

Black Soldier Fly Larvae Ingredients Receive FDA Recommendation for Poultry Diets

September 10, 2018

Read More

Intrexon Business Update and Conference Call

August 9, 2018

Read More

Intrexon to Present at the Jefferies 2018 Global Industrials Conference

August 3, 2018

Read More

Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th

August 2, 2018

Read More

Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock

June 29, 2018

Read More

Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock

June 27, 2018

Read More

Oxitec to Apply New Generation of Self-Limiting Mosquito Technology to Malaria-Spreading Mosquitoes

June 9, 2018

– Oxitec’s first step into global malaria vector control efforts in partnership with the Bill & Melinda Gates Foundation – Agreement covers the first strain of Oxitec’s genetically-engineered mosquitoes specifically designed to combat malaria vector – Read More

Isolation and Recombinant Expression of Key Enzyme for Opioid Production

May 29, 2018

Long Postulated Enzyme Thebaine Synthase Potentiates Efficient Biosynthesis of Opioids by Increasing Thebaine Titers >20-fold in Engineered Yeast Strains Read More

Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001

May 21, 2018

Milestone represents the first ever triple effector gene therapy for heart failure Read More

Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference

May 14, 2018

Read More

Intrexon Announces First Quarter 2018 Financial Results

May 10, 2018

- Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million - Read More

Intrexon to Announce First Quarter 2018 Financial Results on May 10th

May 3, 2018

Read More

Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use

April 16, 2018

Read More

ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes

March 29, 2018

A unique combination approach to oral tolerance made possible by L. lactis therapeutic protein delivery Read More

Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results

March 1, 2018

- Quarterly GAAP revenues of $77.0 million and net loss attributable to Intrexon of $27.3 million including non-cash charges of $41.5 million - Read More

Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st

February 22, 2018

Read More

Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

January 19, 2018

Read More

Intrexon Prices Public Offering of Common Stock

January 17, 2018

Read More

Intrexon Announces Proposed Public Offering of Common Stock

January 16, 2018

Read More

Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8

January 4, 2018

Read More

Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference

January 4, 2018

Read More

Intrexon Corporation Annual CEO Letter

January 2, 2018

Read More

Intrexon Announces Key Management Appointments

November 27, 2017

Read More

Intrexon to Present at the Stifel 2017 Healthcare Conference

November 10, 2017

Read More

News

Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®

June 28, 2018

Read More

Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy

June 18, 2018

Read More

Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

May 21, 2018

Read More

Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2018

Read More

Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized Scleroderma

March 6, 2018

Read More

Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

January 30, 2018

Read More

Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference

January 9, 2018

Read More

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

December 10, 2017

Read More

ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting

November 20, 2017

Read More

ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology

November 6, 2017

Read More

ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting

November 1, 2017

Read More

Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia

October 31, 2017

Read More

ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors

October 16, 2017

Read More

ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

October 12, 2017

Read More

Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

September 26, 2017

Read More

ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting

September 18, 2017

Read More

ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

September 1, 2017

Read More

Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis

August 31, 2017

Read More

ZIOPHARM Oncology Announces Initiation of Stereotactic Treatment Cohort in Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma

June 28, 2017

Read More

AquaBounty Acquires Fish Farming Facility in Indiana

June 13, 2017

Read More

Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma

June 12, 2017

Read More

Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa

June 8, 2017

Read More

Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference

June 6, 2017

Read More

ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

June 5, 2017

Read More

ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting

May 17, 2017

Read More

Careers

At intrexon, our team is committed to building a better world through better DNA. We strive every day to improve the planet through the engineering of biology, and we invite the World’s most creative and talented individuals to join us in this mission.

“The purpose of the organization of intrexon is to enable dedicated and imaginative people who want to see their contributions benefit our planet. The culture we have built, which includes a very flat organization and the absence of a HQ, unites one thousand people toward a common general object while inspiring each to contribute uniquely.” 
-RJ Kirk, Chairman and CEO of intrexon

If you are ready to join us in creating the code for a better, cleaner, and healthier planet, check out our current job openings.

Join Us

Contact Us

Privacy Disclaimer for website visitors from the European Economic Area: By submitting your personal data through this contact form, you acknowledge having read and understood our Privacy Policy, which you can find here, including the provisions regarding the transfer of your personal data to the United States (as this is where this website is hosted and operated). By requesting us to contact you via this contact form, you expressly agree to such transfer, even though U.S. legislation may not provide sufficient protection of your personal data. If you do not want your personal data to be sent directly to the U.S., please do not use this contact form but contact our European subsidiaries directly at the following e-mail addresses: ABT.info@actobio.com, info@ilh.com, info@oxitec.com. If you have any further questions about the way in which we treat your personal data please contact us as indicated in our Privacy Policy.”

Disclaimer: Any communication or other material that you send to us through the internet or by electronic mail or otherwise, such as any questions, comments, suggestions, investment opportunities, inventions or the like, is and will be deemed to be non-confidential.  Intrexon shall have no obligation of any kind with respect to such information. Intrexon shall be free to use, anywhere in the world, any ideas, concepts, know-how or techniques contained in such communication for any purpose whatsoever, including but not limited to, public and/or third party disclosure, development, manufacture, marketing, and sales.

Notes: If you need to verify employment please fax your request with the employee consent form to (540) 301-2226 attention Human Resources.

If you are a member of the public seeking personal and/or legal DNA-type testing services, you have reached this website in error. Please do not contact Intrexon about such services or to request referrals.

true I have read the disclaimer and agree to its terms.